Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02576119 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects
A Phase 1 study, sponsored by ViiV Healthcare.
- Terminated
- Registry status
- Phase 1
- Development phase
- 315
- Enrollment target
NCT02576119: Clinical Trial Phase 1 study, sponsored by ViiV Healthcare.
NCT02576119 is a Phase 1 study that was terminated before completion, run by ViiV Healthcare. The registered enrollment target is 315 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (425% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02576119, a Phase 1 study, was terminated before completion, sponsored by ViiV Healthcare.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 315 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the effect of multiple doses of BMS-955176 on the QT interval corrected with Fridericia's method (QTcF) in healthy subjects.
Interventions
- DRUG BMS-955176, Placebo (Part 1)
- DRUG BMS-955176, Moxifloxacin, Placebo (Part 2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2015-10-19 |
| Est. Completion | 2016-10-14 |
| Phase | Phase 1 |
Why NCT02576119 stopped before completion
NCT02576119 is an interventional study that assigns participants to a tested intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (425% higher).
The record links to 0 conditions, and to 2 interventions - of which BMS-955176, Placebo (Part 1) is the first listed.
NCT02576119 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02576119 about?
NCT02576119 is a clinical study titled "A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects". The purpose of the study is to determine the effect of multiple doses of BMS-955176 on the QT interval corrected with Fridericia's method (QTcF) in healthy subjects.
What is the current status of trial NCT02576119?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 315 participants. The study started on 2015-10-19. Estimated completion is 2016-10-14.
What interventions are being tested in trial NCT02576119?
The interventions under investigation include: BMS-955176, Placebo (Part 1) (DRUG), BMS-955176, Moxifloxacin, Placebo (Part 2) (DRUG).
Who is sponsoring clinical trial NCT02576119?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02576119's enrollment target sits among peer trials
315 117th of 2000 higher than 1,883 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04812366 · 315 participants · Phase 2
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- NCT05101460 · 315 participants
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
- NCT05897320 · 315 participants · Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- NCT06439082 · 315 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI